First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors James J. HardingChristiane JungelsGhassan K. Abou-Alfa Original Research Article Open access 14 February 2023 Pages: 181 - 193
Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan Ping-Chih HsuSuey-Haur LeeChin-Chou Wang Original Research Article Open access 20 February 2023 Pages: 195 - 207
Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study Hiroki IshiharaYuki NemotoToshio Takagi Original Research Article 21 March 2023 Pages: 209 - 220
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis? Margherita RiminiMara PersanoAndrea Casadei-Gardini Original Research Article 15 March 2023 Pages: 221 - 233
Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma Karolina PiejkoBożena Cybulska-StopaPiotr Rutkowski Original Research Article Open access 11 March 2023 Pages: 235 - 245
Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma Nuri LeeJae Lyun LeeJu-Yeun Lee Original Research Article 24 February 2023 Pages: 247 - 255
Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board Klara DormanDanmei ZhangC. Benedikt Westphalen Original Research Article Open access 28 February 2023 Pages: 257 - 267
FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer Maureen CaligiuriGrace L. WilliamsSylvie M. Guichard Original Research Article Open access 24 February 2023 Pages: 269 - 285
Abemaciclib: A Review in Early Breast Cancer with a High Risk of Recurrence Simon FungHannah A. Blair Adis Drug Evaluation 24 February 2023 Pages: 287 - 294
Relugolix: A Review in Advanced Prostate Cancer Matt Shirley Adis Drug Evaluation Open access 18 January 2023 Pages: 295 - 302
Selinexor–Bortezomib–Dexamethasone: A Review in Previously Treated Multiple Myeloma Yahiya Y. Syed Adis Drug Evaluation 09 January 2023 Pages: 303 - 310
Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies Sanjay PopatMyung-Ju AhnJames Chih-Hsin Yang Correction 08 February 2023 Pages: 311 - 311
